Clinical trial Recruiting at 3 sites Observational Ages 18 and up

Histology and molecular profiling of small-bowel biopsies to improve celiac care

Official title: Histological and Molecular Profiling in the Diagnostics and Treatment of Small-Bowel Diseases - A Prospective Cohort Study (The DeepBowel Study)

Run by Tampere University Hospital · NCT07556328 · Data updated 2026-11-12

This project will test whether digital imaging, AI, gene-level profiling, and lab-grown intestinal cells can help diagnose and understand celiac disease and related small-bowel problems in adults having a gastroscopy.

More Celiac Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorTampere University Hospital
Academic / other
Locations3 sites (Tampere and 2 other locations)
StatusRecruiting
StartedNovember 1, 2025
Main results expectedDecember 31, 2035
Study endsDecember 31, 2035
Registry record updatedApril 29, 2026
Trial IDNCT07556328 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) scheduled for a clinically indicated gastroscopy, including those referred for primary celiac diagnostics, healthy controls with negative celiac antibodies, and patients with small‑bowel mucosal injury not responding to a gluten‑free diet, are the intended participants.

Probably not a fit

People who are under 18, unable to provide informed consent, have other small‑bowel diseases causing mucosal injury (for healthy control enrollment), or are not undergoing endoscopy are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort collects duodenal biopsies from three adult groups: healthy controls undergoing clinically indicated gastroscopy with negative celiac antibodies, people referred for primary celiac diagnostics, and patients with persistent small-bowel mucosal injury despite a gluten‑free diet. Biopsies will be digitized for AI-based morphometry to establish reference villus-to-crypt ratios and reduce observer variability. Samples will also undergo RNA sequencing to profile molecular pathways and comparison with drug-trial datasets, and intestinal organoids will be grown to model disease progression and refractory injury. Research samples will be pseudonymized and processed at the Tampere University Celiac Disease Research Center, with statistical analyses performed in collaboration with the study statistician.

Why it matters

Potential benefit: If successful, the work could make biopsy readings more accurate and provide molecular markers to guide diagnosis and treatment decisions for celiac and refractory small-bowel disease.

How similar studies have gone: AI and digital morphometry have shown promise in improving histology reproducibility in related work, while combining transcriptomics and organoid modeling in celiac disease is relatively novel and less established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Clinically indicated upper gastrointestinal endoscopy (gastroscopy)
* Written informed consent obtained prior to procedure
* For Group 1 (Healthy Controls): Negative celiac disease antibodies (anti-transglutaminase and/or anti-endomysium); no suspected celiac
* For Group 2 (Celiac Diagnostics): Referred for primary celiac disease diagnostics requiring duodenal biopsy
* For Group 3 (Refractory Injury): Confirmed small-bowel mucosal injury not responsive to a gluten-free diet

Exclusion Criteria:

* For Group 1 (Healthy Controls): Other small-bowel diseases causing mucosal injury, including Crohn's disease and small-bowel ulcers
* Inability to provide written informed consent
* Refusal to participate

Where it's running

  • Hatanpää Specialist Medical Care
    Tampere, Finland
    Recruiting
  • Tampere University Hospital (Tays)
    Tampere, Finland
    Recruiting
  • Valkeakoski Regional Hospital
    Valkeakoski, Finland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.